162 related articles for article (PubMed ID: 37744342)
21. In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer.
Lu L; Ma W; Johnson CH; Khan SA; Irwin ML; Pusztai L
Vaccine; 2023 Mar; 41(12):2073-2083. PubMed ID: 36813666
[TBL] [Abstract][Full Text] [Related]
22. Challenges targeting cancer neoantigens in 2021: a systematic literature review.
Chen I; Chen MY; Goedegebuure SP; Gillanders WE
Expert Rev Vaccines; 2021 Jul; 20(7):827-837. PubMed ID: 34047245
[No Abstract] [Full Text] [Related]
23. Peptide vaccines in early breast cancer.
Criscitiello C; Viale G; Curigliano G
Breast; 2019 Apr; 44():128-134. PubMed ID: 30769238
[TBL] [Abstract][Full Text] [Related]
24. Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information.
Kim S; Kim HS; Kim E; Lee MG; Shin EC; Paik S; Kim S
Ann Oncol; 2018 Apr; 29(4):1030-1036. PubMed ID: 29360924
[TBL] [Abstract][Full Text] [Related]
25. HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer.
Ren Y; Cherukuri Y; Wickland DP; Sarangi V; Tian S; Carter JM; Mansfield AS; Block MS; Sherman ME; Knutson KL; Lin Y; Asmann YW
Oncoimmunology; 2020; 9(1):1744947. PubMed ID: 32523802
[TBL] [Abstract][Full Text] [Related]
26. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
27. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
[TBL] [Abstract][Full Text] [Related]
28. Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses.
Zhang W; Yin Q; Huang H; Lu J; Qin H; Chen S; Zhang W; Su X; Sun W; Dong Y; Li Q
Front Oncol; 2021; 11():628456. PubMed ID: 33928024
[TBL] [Abstract][Full Text] [Related]
29. Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors.
Wang W; Yuan T; Ma L; Zhu Y; Bao J; Zhao X; Zhao Y; Zong Y; Zhang Y; Yang S; Qiu X; Shen S; Wu R; Wu T; Wang H; Gao D; Wang P; Chen L
Adv Sci (Weinh); 2022 Aug; 9(22):e2105810. PubMed ID: 35665491
[TBL] [Abstract][Full Text] [Related]
30. Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines.
Roesler AS; Anderson KS
Methods Mol Biol; 2022; 2410():649-670. PubMed ID: 34914074
[TBL] [Abstract][Full Text] [Related]
31. A multiepitopic theoretical fusion construct based on in-silico epitope screening of known vaccine candidates for protection against wide range of enterobacterial pathogens.
Kumar A; Harjai K; Chhibber S
Hum Immunol; 2019 Jul; 80(7):493-502. PubMed ID: 30769032
[TBL] [Abstract][Full Text] [Related]
32. Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients.
Occhipinti S; Sponton L; Rolla S; Caorsi C; Novarino A; Donadio M; Bustreo S; Satolli MA; Pecchioni C; Marchini C; Amici A; Cavallo F; Cappello P; Pierobon D; Novelli F; Giovarelli M
Clin Cancer Res; 2014 Jun; 20(11):2910-21. PubMed ID: 24668647
[TBL] [Abstract][Full Text] [Related]
33. Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell-derived extracellular vesicles.
Xiong X; Ke X; Wang L; Lin Y; Wang S; Yao Z; Li K; Luo Y; Liu F; Pan Y; Yeung SJ; Helfrich W; Zhang H
J Extracell Vesicles; 2022 Aug; 11(8):e12243. PubMed ID: 35927827
[TBL] [Abstract][Full Text] [Related]
34. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
[TBL] [Abstract][Full Text] [Related]
35. Gene fusion neoantigens: Emerging targets for cancer immunotherapy.
Wang Y; Shi T; Song X; Liu B; Wei J
Cancer Lett; 2021 May; 506():45-54. PubMed ID: 33675984
[TBL] [Abstract][Full Text] [Related]
36. Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4
Basu A; Albert GK; Awshah S; Datta J; Kodumudi KN; Gallen C; Beyer A; Smalley KSM; Rodriguez PC; Duckett DR; Forsyth PA; Soyano A; Koski GK; Lima Barros Costa R; Han H; Soliman H; Lee MC; Kalinski P; Czerniecki BJ
Cancer Immunol Res; 2022 Jan; 10(1):108-125. PubMed ID: 34785506
[TBL] [Abstract][Full Text] [Related]
37. Improvement in neoantigen prediction via integration of RNA sequencing data for variant calling.
Nguyen BQT; Tran TPD; Nguyen HT; Nguyen TN; Pham TMQ; Nguyen HTP; Tran DH; Nguyen V; Tran TS; Pham TN; Le MT; Phan MD; Giang H; Nguyen HN; Tran LS
Front Immunol; 2023; 14():1251603. PubMed ID: 37731488
[TBL] [Abstract][Full Text] [Related]
38. NeoScore Integrates Characteristics of the Neoantigen:MHC Class I Interaction and Expression to Accurately Prioritize Immunogenic Neoantigens.
Borden ES; Ghafoor S; Buetow KH; LaFleur BJ; Wilson MA; Hastings KT
J Immunol; 2022 Apr; 208(7):1813-1827. PubMed ID: 35304420
[TBL] [Abstract][Full Text] [Related]
39. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
40. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
